That said, the treatment is still in the very early stages of clinical trials, implying there is still some time before the drug can even move to late stage trials, let alone file for approval subject to a positive outcome of the upcoming studies. Mr. Beitel is responsible for developing and implementing strategic growth initiatives. We believe the stock has rallied meaningfully and it is likely to see downside after the recent uptick. Citi analyst Yigal Nochomovitz lowered the firm's price target on Fate Therapeutics to $9 from $80 and keeps a Buy rating on the shares. In announcing the J&J deal, Fate also warned of coronavirus-related "delays or disruptions in patient enrollment and site initiation" that will affect the timing of its clinical trials. Given the current momentum in the stock, and based on our machine learning analysis of trends in the stock price over the last few years, we believe that there is an 64% chance of a rise in FATE stock over the next month (twenty one trading days). According to analysts' consensus price target of $24.69, Fate Therapeutics has a forecasted upside of 305.4% from its current price of $6.09. More importantly, there is 60% probability of a positive return over the next twenty-one trading days and a 53% probability of a positive excess return after a -5% change over five trading days, based on historical data. Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. View analysts price targets for FATE or view top-rated stocks among Wall Street analysts. Fate Therapeutics, Inc. (FATE) NasdaqGM - NasdaqGM Real Time Price. Lazard Asset Management LLC Raises Stake in CDW Co. (NASDAQ:CDW), Verition Fund Management LLC Raises Stock Position in Teradyne, Inc. (NASDAQ:TER), Get a free copy of the StockNews.com research report on Fate Therapeutics (FATE). J&J sues Amgen over plan to sell ulcerative colitis drug similar to Stelara. Among them: Pfizer's wide-ranging deal with Allogene Therapeutics in 2018 as well as Bayer's buyout of BlueRock Therapeutics and investment in Century Therapeutics last year. But how would these numbers change if you are interested in holding FATE stock for a shorter or a longer time period? Fate Therapeutics has raised a total of $1.2B in funding over 16 rounds. Answer: The average return after a rise is understandably lower than a fall as detailed in the previous question. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Question 3: What about the average return after a rise if you wait for a while? The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter. Given that the company does not have any marketable products currently, it generates revenues primarily from collaboration with other pharmaceutical companies. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. . Entering this year, the allogeneic field looked set to take some steps forward. However, any positive outcome on the trials related to the companys solid tumor treatment candidates will likely result in stock price growth. Quantbot Technologies LP bought a new stake in shares of Fate Therapeutics during the 3rd quarter valued at about $69,000. It appears so. Investigator-assessed ORR was 11.4% in patients with NPCB, 16.9% with PCB, and 25.0% in CPI-nave. As analyst firm Jefferies noted in March, Precision,AllogeneTherapeutics and CRISPRTherapeutics, which each use different off-the-shelf approaches, could all produce notable human data this year. Subjects who previously took part in a Fate Therapeutics study and received genetically changed NK cells will take part in this long-term follow-up study. Opinions expressed by Forbes Contributors are their own. Private Advisor Group LLC grew its stake in shares of Fate Therapeutics by 25.7% during the 1st quarter. Fate Therapeutics, Inc. has a 52-week low of $4.02 and a 52-week high of $43.12. The J&J partnership does give Fate some breathing room. Also, CEO J Scott Wolchko sold 45,907 shares of the stock in a transaction dated Tuesday, January 10th. 2 employees have rated Fate Therapeutics Chief Executive Officer Scott Wolchko on Glassdoor.com. Under terms of the agreement, Fate will receive $50 million in upfront cash, as well as a $50 million equity investment by Janssen. While FATE stock may be overvalued, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. Therefore we cannot guarantee that our site fully works in Internet Explorer. Raymond James & Associates now owns 29,436 shares of the biopharmaceutical companys stock worth $1,141,000 after purchasing an additional 8,790 shares during the period. Notably, though, the stock is likely to beat S&P500 returns by 4% over the next month (twenty-one trading days). The. [Updated: 2/10/2021] Can The FATE Stock Rally Continue? How were Fate Therapeutics' earnings last quarter? See allTrefis Price EstimatesandDownloadTrefis Datahere, Whats behind Trefis? Jeereddi Investments LP Increases Position in Alphabet Inc. Boothbay Fund Management LLC Buys Shares of 4,680 Sonoco Products. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. FATE Fate Therapeutics Inc 6,209 $6.11 $0.02 (0.33%) Today Market Cap $583.99M Volume (M) 1.52M 52-Wk High $43.12 52-Wk Low $4.02 About Feed Sentiment Fundamentals News There is no chart data available for this period 1d 1w 1m 3m 6m 1y All Sentiment Score Message Volume Score Disclaimer: This is informational only. [Updated: 3/30/2021] Can FATE Stock Rebound? In other Fate Therapeutics news, Director John Mendlein bought 88,048 shares of Fate Therapeutics stock in a transaction that occurred on Wednesday, January 11th. Going by the consensus revenue estimate of $20.4 million in 2020, FATE stock is trading at 456x its RPS of $0.25, which appears to be very high. You may opt-out by. The biopharmaceutical company earns $-212,150,000.00 in net income (profit) each year or ($2.91) on an earnings per share basis. Drug price reforms and regulatory scrutiny present challenges for large drugmakers, although successes in Alzheimers and obesity have brought new opportunities, too. Hagens Berman is a global plaintiffs' rights complex litigation law firm focusing on corporate accountability through class-action law. Last updated: Feb 26, 2023 Powered by IT Spend by Aberdeen This year, Fate Therapeutics is projected to spend $682.2K on IT, according to Aberdeen. By creating a free account, you agree to our, In Britain, warm hubs emerge to beat soaring energy costs, In Chicago, adapting electric buses to winters challenges, Global race to boost electric vehicle range in cold weather, Ukraine ally Kallas fights for reelection in Estonia vote, Paid express lanes grow more popular in once-reluctant South, Pot vote has Oklahoma hungry to rake in green from Texas, Home Depot Stock Earnings Slide, Long Term Value Still There, AbbVie Stock Still a Solid Buy Despite Challenges, President, Chief Executive Officer & Director, Chief Financial Officer & Accounting Officer, Senior Vice President-Technical Operations. Topics covered: Pharma, biotech, FDA, gene therapy, clinical trials, drug pricing and much more. February 28, 2023 - 10:35 am. Fate Therapeutics has a 12 month low of $4.02 and a 12 month high of $43.12. [Updated: 2/10/2021] Can The FATE Stock Rally Continue? Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be mass-produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment, the company said. Fate is working toward a class of treatment that is based on NK cells. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. The early stage company is also eligible to receive up to $1.8 billion in development and. Answer: If you buy and hold Fate Therapeutics stock, the expectation is over time the near term fluctuations will cancel out, and the long-term positive trend will favor you - at least if the company is otherwise strong. The revenues are expected to see a sharp jump of over 90% to $20.4 million in 2020, due to collaboration agreements with Janssen and Ono. Question 3: What about the average return after a rise if you wait for a while? If youre new to trading, then youve probably heard the wrong thing about optionsthat theyre risky, unpredictable, or difficult. Eight of 11 lymphoma patients who received one Fate NK cell therapy, FT516, have shown evidence of a response, as have 10 of 14 given . While the usual process is to create a different batch for each patient from their own stem cells, Fate is intending for mass production of such treatment. Its pretty powerful to test the trend for yourself for Fate Therapeutics stock by changing the inputs in the charts above. The average twelve-month price prediction for Fate Therapeutics is $24.69 with a high price target of $90.00 and a low price target of $7.00. While we believe that FATE stock is richly valued, the market potential is huge, especially in multi-billion dollar - oncology treatments. Get the free daily newsletter read by industry experts. According to the Trefis Machine Learning Engine, which identifies trends in a companys stock price using historical stock data, returns for FATE stock average around 6% in the next one-month (twenty-one trading days) period after experiencing a 5% fall in a week (five trading days). Purchases New Holdings in Ball Co. Kroger (NYSE:KR) Shares Gap Up on Better-Than-Expected Earnings, AlphaCrest Capital Management LLC Trims Position in Best Buy Co., Inc. (NYSE:BBY), AlphaCrest Capital Management LLC Sells 26,238 Shares of Hormel Foods Co. (NYSE:HRL), Burlington Stores, Inc. (NYSE:BURL) Shares Sold by Eaton Vance Management, Tudor Investment Corp Et Al Increases Holdings in Artivion, Inc. (NYSE:AORT), BlackRock Inc. Interestingly, though, if a stock has gained over the last few days, you would do better to avoid short-term bets for most stocks - although FATE stock appears to be an exception to this general observation. Is the average return for Fate Therapeutics stock higher over the subsequent month after Case 1 or Case 2? Their FATE share price forecasts range from $7.00 to $90.00. Given the current momentum in the stock, and based on our machine learning analysis of trends in the stock price over the last few years, we believe that there is an 64% chance of a rise in FATE stock over the next month (twenty one trading days). FATE stock has rallied from $22 to $114, significantly outperforming the S&P which moved 70% over the same period, with the resumption of economic activities as lockdowns are gradually lifted and vaccines are being approved in multiple countries. Segall Bryant & Hamill LLC lifted its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Get Rating) by 2.0% in the third quarter, Holdings Channel.com reports. However, looking at the P/S for Fate is not helpful given the company doesnt have any marketable product yet, and it is more of a story of exciting products in the pipeline. PNC Financial Services Group Inc. now owns 6,737 shares of the biopharmaceutical companys stock worth $260,000 after buying an additional 986 shares during the last quarter. What other stocks do shareholders of Fate Therapeutics own? But how would these numbers change if you are interested in holding FATE stock for a shorter or a longer time period? American Consumer News, LLC dba MarketBeat 2010-2023. HighTower Advisors LLC boosted its holdings in shares of Fate Therapeutics by 5.9% in the 1st quarter. Glassdoor has salaries, wages, tips, bonuses, and hourly pay based upon employee reports and estimates. Funding. The rise can largely be attributed to increased investor expectations from Fates pipeline, which focuses on a class of treatment that is based on Natural Killer cells. A change of 9.3% or more over five trading days (one week) is a 18% likelihood event, which has occurred 352 times out of 1945 in the last 8 years, Of these 352 instances, the stock has seen a positive movement over the next five trading days on 174 occasions, A change of 7% or more over ten trading days is a 31% likelihood event, which has occurred 597 times out of 1945 in the last 8 years, Of these 597 instances, the stock has seen a positive movement over the next ten trading days on 266 occasions, A change of 3.6% or more over twenty-one trading days is a 43% likelihood event, which has occurred 831 times out of 1944 in the last 8 years, Of these 831 instances, the stock has seen a positive movement over the next twenty-one trading days on 464 occasions, A change of 16% or more over 5 trading days is a 9% likelihood event, which has occurred 114 times out of 1256 in the last 5 years, A change of 13% or more over 10 trading days is a 20% likelihood event, which has occurred 252 times out of 1240 in the last 5 years. Fate Therapeutics, Inc engages in the development of programmed cellular immunotherapies for cancer and immune disorder. The partnership doesn't include any of the other treatments currently in Fate's pipeline. Subscribe to BioPharma Dive for top news, trends & analysis, The free newsletter covering the top industry headlines, By Christopher Newman and Jonathan Gardner , A preclinical trial by the U.S. National Institutes of Health validates the efficacy of Uric A, EUCOPE adds nine new innovative members to its network, From EUCOPE - European Confederation of Pharmaceutical Entrepreneurs, Ymmunobio Welcomes Dr. Kanda and Dr. Khairnar to Advisory Board, Vial Announces the Addition of Dr. Rajat N Agrawal to their Ophthalmology CRO Scientific Advis, By signing up to receive our newsletter, you agree to our, disrupting study enrollment and treatment, Bayer backs cell therapy startup with $215M in funding, Bayer Buys Out BlueRock, Betting at Least $240M More on Cell Therapy Work, 5 questions facing the pharma industry in 2023, FDA clears Intellia to start US tests of in vivo gene editing drug, Novartis takes step toward expanding supply of in-demand cancer drug, Bristol Myers, J&J plan tests of new blood thinner in nearly 50,000 patients, Exelixis reports trial failure for cancer drug combination, How to Implement a Healthy Content Moderation Strategy, How To Build Affordability Programs With Real-time Data, FDA has new power to hold drugmakers accountable. Janssen will also cover the funding costs of the R&D of the collaboration candidates. The stock price of Fate Therapeutics (NASDAQ: FATE), a biopharmaceuticals company focused on oncology and immunology treatments based on natural killer T-Cell programs, has seen a 9% rise. Fate Therapeutics has been the subject of 17 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Fate Therapeutics saw its shares in the red after-hours Thursday night as durability concerns cast a shadow over its latest blood cancer data drop. Raymond James & Associates raised its stake in Fate Therapeutics by 42.6% during the first quarter. | March 3, 2023 Try the Trefis machine learning engine above to see for yourself how Fate Therapeutics stock is likely to behave after any specific gain or loss over a period. contact@marketbeat.com Assignee: FATE THERAPEUTICS, INC. The San Diego biotech is getting $100 million to produce up to four new therapies that J&J will have the option to license, while J&J covers the associated R&D costs. Fate Therapeutics has an overall rating of 2.9 out of 5, based on over 76 reviews left anonymously by employees. The disclosure for this sale can be found here. Some Fun Scenarios, FAQs & Making Sense of Fate Therapeutics Stock Movements:uestion 1: Is the average return for Fate Therapeutics stock higher after a drop? It has seen positive findings from early trials for FT500, preventing disease progression for 11 out of 15 patients, something that has kept the stock price buzzing of late. Eli Lilly Slashed Insulin Prices. CI Investments Inc. boosted its stake in shares of Fate Therapeutics by 413.7% during the 4th quarter. Looking at the recent rally, the 9% rise for FATE stock over the last five days compares with a 0.7% growth seen in the broader S&P 500 index. Kessler Investment Group LLC bought a new stake in shares of Fate Therapeutics during the 3rd quarter valued at about $82,000. Now that FATE stock has seen a rise of 9% in five trading days, can it continue its upward trajectory, or is a decline imminent? It has seen positive findings from early trials for FT500, something that has kept the stock price buzzing of late. The definitive agreement will see the payment of up to $1bn to Exonics' equity holders if future development and regulatory milestones are met for certain programmes. While the usual process is to create a different batch for each patient from their own stem cells, Fate is intending for mass production of such treatment. Also, Director John Mendlein purchased 88,048 shares of the businesss stock in a transaction on Wednesday, January 11th. Real-time analyst ratings, insider transactions, earnings data, and more. We believe the stock has rallied meaningfully and it is likely to see downside after the recent uptick. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. Shares have lost about 21% in that time frame, underperforming the S&P 500. The partnership will leverage San Diego-based Fate Therapeutics induced pluripotent stem cell (iPSC) product platform and Janssens proprietary tumor-targeting antigen binders to create novel CAR NK and CAR T-Cell product candidates that will be developed against up to four tumor-associated antigens for hematologic malignancies and solid tumors. 22 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. New York, NY-based Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of the central nervous system, disorders for which there are limited. The data from the trials showed that eight of eleven patients being evaluated for assessment of safety and efficacy of the FT516 treatment achieved an objective response, while six of those patients achieved a complete response. You may opt-out by. Only slivers of human data have been published thus far. sharewise - Stocks and the Wisdom of the crowd. Additionally, Fate has the right to co-commercialize the candidates should they be approved and share equally in profits and losses, the company said in its announcement. She looks for companies that are changing the . This rating has decreased by -28% over the last 12 months. Following the completion of the transaction, the chief executive officer now owns 385,639 shares of the companys stock, valued at approximately $2,020,748.36. Tesla Investors Arent Impressed With Elon Musk. The Axsome Therapeutics stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock, but the stock has a general sell signal from the relation between the two signals where the long-term average is above the short-term average. Envestnet Asset Management Inc. now owns 8,734 shares of the biopharmaceutical companys stock worth $339,000 after buying an additional 1,457 shares during the last quarter. The outperformance of FATE can be attributed to positive findings from early clinical trials of FT500 and FT516 treatments. In related news, CFO Edward J. Dulac III sold 7,331 shares of the companys stock in a transaction dated Tuesday, January 10th. The company is currently working on multiple programs, including FT516 for the treatment of acute myeloid leukemia and B-cell lymphoma, FT596 to treat B-cell lymphoma, FT538 to treat AML and multiple myeloma, FT576 to treat multiple myeloma, FT500, FT516, FT-ONO2, and FATE-NK100 for the treatment of advanced solid tumors. 1985 - 2023 BioSpace.com. Shares of Fate Therapeutics were up more than 21% in premarket trading after the company announced a multi-billion dollar deal with Janssen Biotech to develop cell therapies for the treatment of cancer. Per deal terms, J&J will buy $50 million Fate shares at $31 apiece,a roughly 47% premium to Fate's $21.07 closing price on Thursday. Fates revenue did grow a solid 160% from $4.1 million in 2017 to $10.7 million in 2019. If response rates for its treatments fall, as is usually the case in cancer trials, this stock . 40% of employees would recommend working at Fate Therapeutics to a friend and 22% have a positive outlook for the business. Zoom Video Communications, Inc. (NASDAQ:ZM) Shares Acquired by BlackRock Inc. BlackRock Inc. Lowers Position in APA Co. (NASDAQ:APA), Piper Sandler Boosts Duolingo (NYSE:DUOL) Price Target to $127.00, BlackRock Inc. Cuts Holdings in NortonLifeLock Inc. (NASDAQ:NLOK), Altair Engineering Inc. (NASDAQ:ALTR) Insider Sells $161,325.00 in Stock, Caisse DE Depot ET Placement DU Quebec Has $2.15 Million Position in Franklin Resources, Inc. (NYSE:BEN), Capital Fund Management S.A. Makes New Investment in CVR Energy, Inc. (NYSE:CVI), 12,000 Shares in Stratasys Ltd. (NASDAQ:SSYS) Purchased by Gabelli Funds LLC. Twitter. Finally, Great West Life Assurance Co. Can bought a new stake in shares of Fate Therapeutics during the 3rd quarter valued at about $91,000. Now, is FATE stock poised to gain further? View which stocks are hot on social media with MarketBeat's trending stocks report. Using the recent trend (20% fall in a week) and seven years of historical stock data, the Trefis AI engine finds that the stock will likely move 15.1% over the next one month (twenty-one trading days), outperforming the broader indices. Shares climbed about 20%, to around $25 apiece, in pre-market trading Friday. Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), CRISPR Therapeutics (CRSP), Juno Therapeutics (JUNO), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Sorrento Therapeutics (SRNE) and Gilead Sciences (GILD). Will Boston Scientific Stock See Higher Levels? ta petro employee handbook. The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023. All rights reserved. While the usual process is to create a different batch for each patient from their own stem cells, Fate is intending for mass production of such treatment. Powered by Madgex Job Board Software. 17.34% of the stock of Fate Therapeutics is held by insiders. A class action has already been filed. Insiders have sold a total of 75,708 shares of company stock worth $396,710 in the last ninety days. HighTower Advisors LLC now owns 18,361 shares of the biopharmaceutical companys stock valued at $714,000 after purchasing an additional 1,016 shares during the last quarter. It appears so. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Going by the consensus revenue estimate of $20.4 million in 2020, FATE stock is trading at 456x its RPS of $0.25, which appears to be very high. Out of 352 instances in the last eight years that Fate Therapeutics stock saw a five-day rise of 9% or more, 178 of them resulted in FATE stock rising over the subsequent one month period (twenty-one trading days). What is a Good Dividend Yield? The revenues are expected to see a sharp jump of over 90% to $20.4 million in 2020, due to collaboration agreements with Janssen and Ono. Fate Therapeutics had a negative trailing twelve-month return on equity of 50.86% and a negative net margin of 292.55%. What is a Good Dividend Yield? It has seen positive findings from early trials for FT500, something that has kept the stock price buzzing of late. In the past three months, Fate Therapeutics insiders have bought 75.98% more of their company's stock than they have sold. Owens Corning (NYSE:OC) Shares Sold by Capital Fund Management S.A. Nucor Co. (NYSE:NUE) Shares Sold by Blueshift Asset Management LLC, Stratasys Ltd. (NASDAQ:SSYS) Stock Holdings Lifted by AlphaCrest Capital Management LLC, Blueshift Asset Management LLC Lowers Stock Position in Urban Outfitters, Inc. (NASDAQ:URBN). Posted by Defense World Staff on Mar 4th, 2023. No additional study drug will be given, but subjects can receive other therapies for their cancer while they . Opinions expressed by Forbes Contributors are their own. About Fate Therapeutics, Inc. How many employees does Fate Therapeutics have? The biopharmaceutical company reported ($0.58) earnings per share for the quarter, beating analysts' consensus estimates of ($0.86) by $0.28. The Class A ordinary shares and warrants of BAC trade on the Nasdaq Capital Market under the symbols "BIOT" and "BIOTW," respectively. You can test the chance of recovery over different time intervals of a quarter, month, or even just one day! Inventors: Bahram Valamehr, Peter Flynn, Ramzey Abujarour, Megan Robinson Methods and compositions for inducing hematopoietic cell differentiation Patent number: 11162076 Abstract: The invention provides culture platforms, cell media, and methods of differentiating pluripotent cells into hematopoietic cells. Purchases New Holdings in Ball Co. (NYSE:BALL), Blueshift Asset Management LLC Sells 21,016 Shares of Dell Technologies Inc. (NYSE:DELL), Cary Street Partners Investment Advisory LLC Has $126,000 Stock Holdings in Yum China Holdings, Inc. (NYSE:YUMC). CULVER CITY & EL SEGUNDO, Calif., March 9, 2021 ImmunityBio, Inc. and NantKwest, Inc. (NASDAQ: NK), today announced the completion of their previously announced 100% stock-for-stock merger.This follows the satisfaction of all customary closing conditions, including approval of the merger by a majority of unaffiliated shareholders of . The stock price of Fate Therapeutics (NASDAQ: FATE), a biopharmaceuticals company focused on oncology and immunology treatments based on natural killer T-Cell programs, has seen a large 20%. At Tuesday's closing price,. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Most of the 18x rise of the last 3 years can be attributed to expansion of its P/S multiple, as the company does not have any marketable product yet. See our analysis on Fate Therapeutics Stock Chances of Rise for more details. The shares were sold at an average price of $5.24, for a total value of $240,552.68. FATE stock fares better after Case 1, with an average return of 6% over the next month (21 trading days) under Case 1 (where the stock has just suffered a 5% loss over the previous week), versus, an average return of 3.8% for Case 2. What is Scott Wolchko's approval rating as Fate Therapeutics' CEO? View the best growth stocks for 2023 here. FATE stock has rallied from $22 to $114, significantly outperforming the S&P which moved 70% over the same period, with the resumption of economic activities as lockdowns are gradually lifted and vaccines are being approved in multiple countries. Lazard Asset Management LLC owned approximately 0.17% of Fate Therapeutics worth $3,616,000 at the end of the most recent quarter. fate therapeutics buyout. Per deal terms, J&J will buy $50 million Fate shares at $31 apiece, a roughly 47% premium to Fate's $21.07 closing price on Thursday. You can test the chance of recovery over different time intervals of a quarter, month, or even just one day! In other news, CFO Edward J. Dulac III sold 7,331 shares of the businesss stock in a transaction that occurred on Tuesday, January 10th.
Hartford Public Schools Human Resources,
Fire In Auburndale, Fl Today,
Articles F
